x
Filter:
Filters applied
- Oncology
- Research ArticleRemove Research Article filter
- Freedland, Stephen JRemove Freedland, Stephen J filter
Publication Date
Please choose a date range between 2016 and 2019.
Author
- Moreira, Daniel M3
- Abern, Michael R1
- Amling, Christopher L1
- Andriole, Gerald L1
- Andriole, Gerald L Jr1
- Aronson, William J1
- Beverly, Devon1
- Castro-Santamaria, Ramiro1
- Cooperberg, Matthew R1
- de Hoedt, Amanda1
- Frank, Jennifer1
- Freitas, Daniel M1
- Grant, Delores J1
- Guerrios-Rivera, Lourdes1
- Howard, Lauren1
- Howard, Lauren E1
- Hoyo, Cathrine1
- Kane, Christopher J1
- Mima, Mahmoud1
- Ohlander, Samuel J1
- Pagani, Rodrigo L1
- Schwarzman, Logan S1
- Skove, Stephanie L1
- Terris, Martha K1
Oncology
4 Results
- Oncology
Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy
UrologyVol. 137p97–101Published online: November 13, 2019- Logan S. Schwarzman
- Rodrigo L. Pagani
- Samuel J. Ohlander
- Mahmoud Mima
- Michael R. Abern
- Gerald L. Andriole
- and others
Cited in Scopus: 4To evaluate whether total serum PSA, free-PSA ratio and PSA density have similar diagnostic properties for detecting prostate cancer (PCa) and clinically-significant (cs) PCa in men with normal testosterone compared to men with low testosterone with a prior negative biopsy. - Oncology
Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence
UrologyVol. 108p129–134Published online: July 19, 2017- Stephanie L. Skove
- Lauren E. Howard
- William J. Aronson
- Martha K. Terris
- Christopher J. Kane
- Christopher L. Amling
- and others
Cited in Scopus: 15To evaluate the association between the prostate-specific antigen (PSA) nadir level and the time to nadir (TTN) with biochemical recurrence (BCR) risk after radical prostatectomy (RP) in the Shared Equal-Access Research Cancer Hospital (SEARCH) database. - Oncology
Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort
UrologyVol. 105p129–135Published online: April 10, 2017- Lourdes Guerrios-Rivera
- Lauren Howard
- Jennifer Frank
- Amanda De Hoedt
- Devon Beverly
- Delores J. Grant
- and others
Cited in Scopus: 14To test multiple adiposity measures and prostate cancer (PC) risk in men undergoing prostate biopsy. We hypothesized that body mass index (BMI), body fat, and waist circumference would be highly correlated, and all would be associated with aggressive PC, but not overall risk. - Oncology
Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy
UrologyVol. 103p161–166Published online: December 23, 2016- Daniel M. Freitas
- Gerald L. Andriole Jr
- Ramiro Castro-Santamaria
- Stephen J. Freedland
- Daniel M. Moreira
Cited in Scopus: 9To evaluate whether baseline prostate atrophy (PA) extent is associated with prostate cancer (PCa) incidence at 2-year repeat prostate biopsy in a clinical trial with systematic biopsies.